SynthesisPLoS neglected tropical diseases2022
Estimation of the morbidity and mortality of congenital Chagas disease: A systematic review and meta-analysis.
Synthesis in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Estimation of the morbidity and mortality of congenital Chagas disease: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2022Pooled it
- Article
- Trypanosoma cruzi infection in pregnancy: New approaches to address the diagnosis and follow-up of women and newborns.PLoS neglected tropical diseases · 2026Review
- Engineering a nifurtimox nanosuspension: toward improved pharmaceutical attributes.Drug delivery and translational research · 2026Article
- Chagas Disease in the 21st Century: Global Spread, Ecological Shifts, and Research Frontiers.Biology · 2025Review
- Cost-effectiveness analysis of screening for congenital Chagas disease in a non-endemic area.Nature communications · 2025Article
- Beyond Mosquitoes: A Review of Pediatric Vector-Borne Diseases Excluding Malaria and Arboviral Infections.Pathogens (Basel, Switzerland) · 2025Review
- Identification of seropositive cases of Chagas disease in pregnant women in a non-endemic risk area of the state of Mexico: The importance of screening prenatal.Parasite epidemiology and control · 2025Article
- Understanding Host-Pathogen Interactions in Congenital Chagas Disease Through Transcriptomic Approaches.Pathogens (Basel, Switzerland) · 2025Review
- Prevalence ofTropical medicine and infectious disease · 2024Article
- Trypanosoma cruzi Infection in Pregnancies without Congenital Transmission Is Associated with Reduced Fetal Growth: A Cross-Sectional Study in Argentina, Honduras, and Mexico.The American journal of tropical medicine and hygiene · 2024Article
- Organic solvent-free benznidazole nanosuspension as an approach to a novel pediatric formulation for Chagas disease.Therapeutic delivery · 2024Article
- Chagas Disease in Europe.Tropical medicine and infectious disease · 2023Review
- Chagas Disease Maternal Seroprevalence and Maternal-Fetal Health Outcomes in a Parturition Cohort in Western El Salvador.Tropical medicine and infectious disease · 2023Article
- The transcriptome landscape of 3D-cultured placental trophoblasts reveals activation of TLR2 and TLR3/7 in response to lowFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease is caused by the parasite Trypanosoma cruzi which can be transmitted from mother to baby during pregnancy. There is no consensus on the proportion of infected infants with clinical signs of congenital Chagas disease (cCD). The objective of this systematic review is to determine the burden of cCD. Articles from journal inception to 2020 reporting morbidity and mortality associated with cCD were retrieved from academic search databases. Observational studies, randomized-control trials, and studies of babies diagnosed with cCD were included. Studies were excluded if they were case reports or series, without original data, case-control without cCD incidence estimates, and/or did not report number of participants. Two reviewers screened articles for inclusion. To determine pooled proportion of infants with cCD with clinical signs, individual clinical signs, and case-fatality, random effects meta-analysis was performed. We identified 4,531 records and reviewed 4,301, including 47 articles in the narrative summary and analysis. Twenty-eight percent of cCD infants showed clinical signs (95% confidence interval (CI) = 19.0%, 38.5%) and 2.2% of infants died (95% CI = 1.3%, 3.5%). The proportion of infected infants with hepatosplenomegaly was 12.5%, preterm birth 6.0%, low birth weight 5.8%, anemia 4.9%, and jaundice 4.7%. Although most studies did not include a comparison group of non-infected infants, the proportion of infants with cCD with clinical signs at birth are comparable to those with congenital toxoplasmosis (10.0%-30.0%) and congenital cytomegalovirus (10.0%-15.0%). We conclude that cCD burden appears significant, but more studies comparing infected mother-infant dyads to non-infected ones are needed to determine an association of this burden to cCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.